Vyne Therapeutics Inc


Vyne Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2454
  • Today's Change-0.010 / -3.76%
  • Shares traded47.00
  • 1 Year change-56.60%
  • Beta1.4910
Data delayed at least 15 minutes, as of Jan 30 2023 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • VYNE:NAQ price moved over +4.44% to 0.24
  • VYNE:NAQ price falls below 15-day moving average to 0.2414 at 09:34 GMT
  • VYNE:NAQ price rises above 15-day moving average to 0.2422 at 11:57 GMT
  • VYNE:NAQ price rises above 15-day moving average to 0.24 at 09:30 GMT

Key statistics

On Monday, Vyne Therapeutics Inc (VYNE:NAQ) closed at 0.2454, 121.68% above the 52 week low of 0.1107 set on Dec 23, 2022.
52-week range
0.1107Dec 23 20220.79Apr 01 2022
Markit short selling activity
Previous close0.2454
Average volume454.89k
Shares outstanding58.04m
Free float57.06m
P/E (TTM)--
Market cap14.24m USD
EPS (TTM)-0.675
Data delayed at least 15 minutes, as of Jan 30 2023 21:00 GMT.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.